The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C
Open accessAbstract
BACKGROUND/AIMS While several risk factors for the histological progression of chronic hepatitis C have been identified, the contribution of HCV genotypes to liver fibrosis evolution remains controversial. The aim of this study was to assess independent predictors for fibrosis progression. METHODS We identified 1189 patients from the Swiss Hepatitis C Cohort database with at least one biopsy prior to antiviral treatment and assessable date of infection. Stage-constant fibrosis progression rate was assessed using the ratio of fibrosis Metavir score to duration of infection. Stage-specific fibrosis progression rates were obtained using a Markov model. Risk factors were assessed by univariate and multivariate regression models. RESULTS Independent risk factors for accelerated stage-constant fibrosis progression (>0.083 fibrosis units/year) included male sex (OR=1.60, [95% CI 1.21-2.12], P<0.001), age at infection (OR=1.08, [1.06-1.09], P<0.001), histological activity (OR=2.03, [1.54-2.68], P<0.001) and genotype 3 (OR=1.89, [1.37-2.61], P<0.001). Slower progression rates were observed in patients infected by blood transfusion (P=0.02) and invasive procedures or needle stick (P=0.03), compared to those infected by intravenous drug use. Maximum likelihood estimates (95% CI) of stage-specific progression rates (fibrosis units/year) for genotype 3 versus the other genotypes were: F0-->F1: 0.126 (0.106-0.145) versus 0.091 (0.083-0.100), F1-->F2: 0.099 (0.080-0.117) versus 0.065 (0.058-0.073), F2-->F3: 0.077 (0.058-0.096) versus 0.068 (0.057-0.080) and F3-->F4: 0.171 (0.106-0.236) versus 0.112 (0.083-0.142, overall P<0.001). CONCLUSIONS This study shows a significant association of genotype 3 with accelerated fibrosis using both stage-constant and stage-specific estimates of fibrosis progression rates. This observation may have important consequences for the management of patients infected with this genotype.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Natural history of liver fibrosis progression in patients with chronic hepatitis C
Poynard, T., Bedossa, P., & Opolon, P. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07642-8 · Cited by 3,011
Lauer, G. M., & Walker, B. D. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107053450107 · Cited by 2,973
Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients
Benhamou, Y., Bochet, M., Di Martino, V., Charlotte, F., Azria, F., Coutellier, A., Vidaud, M., Bricaire, F., Opolon, P., Katlama, C., et al. (1999) · Hepatology · doi:10.1002/hep.510300409 · Cited by 1,219
Adinolfi, L. E., Gambardella, M., Andreana, A., Tripodi, M.-F., Utili, R., & Ruggiero, G. (2001) · Hepatology · doi:10.1053/jhep.2001.24432 · Cited by 1,059
Epidemiology of viral hepatitis and HIV co-infection
Alter, M. J. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2005.11.004 · Cited by 1,012
Thein, H., Yi, Q., Dore, G. J., & Krahn, M. D. (2008) · Hepatology · doi:10.1002/hep.22375 · Cited by 829
Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c
Poynard, T., Ratziu, V., Charlotte, F., Goodman, Z., McHutchison, J., & Albrecht, J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(00)00097-0 · Cited by 749
Fibrosis in Chronic Hepatitis C Correlates Significantly With Body Mass Index and Steatosis
Hourigan, L. F., Macdonald, G. A., Purdie, D., Whitehall, V. H., Shorthouse, C., Clouston, A., & Powell, E. E. (1999) · Hepatology · doi:10.1002/hep.510290401 · Cited by 674
Leandro, G., Mangia, A., Hui, J., Fabris, P., Rubbia–Brandt, L., Colloredo, G., Adinolfi, L. E., Asselah, T., Jonsson, J. R., Smedile, A., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.03.014 · Cited by 565
Self-citationA comparison of fibrosis progression in chronic liver diseases
Poynard, T., Mathurin, P., Lai, C.-L., Guyader, D., Poupon, R., Tainturier, M.-H., Myers, R. P., Muntenau, M., Ratziu, V., Manns, M., et al. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00413-0 · Cited by 474
Cited by
Epidemiology and natural history of HCV infection
Hajarizadeh, B., Grebely, J., & Dore, G. J. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.107 · Cited by 994
Nelson, D. R., Cooper, J. N., Lalezari, J. P., Lawitz, E., Pockros, P. J., Gitlin, N., Freilich, B. F., Younes, Z. H., Harlan, W., Ghalib, R., et al. (2015) · Hepatology · doi:10.1002/hep.27726 · Cited by 689
Evolving challenges in hepatic fibrosis
Friedman, S. L. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.97 · Cited by 581
Natural history of acute and chronic hepatitis C
Maasoumy, B., & Wedemeyer, H. (2012) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2012.09.009 · Cited by 257
Abnormalities of lipid metabolism in hepatitis C virus infection
Negro, F. (2010) · Gut · doi:10.1136/gut.2009.192732 · Cited by 162
Self-citation
Metadata
- Authors
- Bochud, P.-Y., Cai, T., Overbeck, K., Bochud, M., Dufour, J.-F., Müllhaupt, B., Borovicka, J., Heim, M., Moradpour, D., Cerny, A., Malinverni, R., Francioli, P., & Negro, F.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2009-10
- Volume
- 51
- Issue
- 4
- Pages
- 655-666
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2044203022
- Cited by
- 287
- References
- 29
- FWCI
- 12.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. https://app.cochat.ai/papers/10.1016/j.jhep.2009.05.016
- The paper
- Bochud, P.-Y., Cai, T., Overbeck, K., Bochud, M., Dufour, J.-F., Müllhaupt, B., Borovicka, J., Heim, M., Moradpour, D., Cerny, A., Malinverni, R., Francioli, P., & Negro, F. (2009). Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2009.05.016
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.